Trial designs are becoming more complex. Most of these trials are supported by legacy/older technologies that have limited flexibility to quickly adapt to new trial information. The pharmaceutical industry is reaching a tipping point, where the need for flexibility is outweighing the need to be conservative and risk-averse in this highly-regulated environment.
Can organizations implement today’s regulatory requirements using conventional approaches?
A full-service, highly qualified partner who uses effective technology-enabled financial management services can help ensure efficient site payments, greater transparency into payments on all sides, and satisfied investigators.
How proactive planning to track missing patients will minimize their detrimental effect on study results.
Understand the benefits and challenges of conducting studies in Latin America in addition to some recent changes that could expedite regulatory timelines.
How global site networks can effectively address timeline, budget and data quality concerns, by providing access to multiple experienced sites within a single network, providing cost savings through reduction of the total number of sites used and recruitment of a large volume of patients.
Change the perception of clinical trials by making them less burdensome for patients overall.
- Clinical trial sponsors and clinical supply vendors must fully consider all attributes of their supply chains to ensure continuity of supply post-Brexit. This whitepaper outlines many questions that sponsors and vendors alike should ask
Learn how clinical development technologies and advanced analytics navigate sponsors through the challenges of patient scarcity to transform precision oncology research.
The reasons behind the physician monitors’ reluctance, and what technology needs to offer to convince monitors their work can be more efficient — quickly detecting safety signals and speeding time to submission.
|
|
|
|
|
|
|
|
|